KATP channel Inhibitors
1 drugsAbout KATP channel
The ATP-sensitive potassium channel (KATP) regulates cellular excitability and insulin secretion by coupling cellular metabolism to electrical activity. It is formed by inward-rectifier potassium channel (Kir6.x) and sulfonylurea receptor (SURx) subunits.
Currently, there is no genetic evidence available linking KATP channels to specific diseases. However, their role in key physiological processes makes them attractive targets for therapeutic intervention.
Nateglinide, a small molecule approved in 2009, is the only FDA-approved drug targeting the KATP channel. It is used in the metabolic therapeutic area for managing type 2 diabetes.
Top KATP channel Drugs
Only one company, Rising, has an approved drug targeting KATP channels.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in the target space.
KATP channel Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets KATP channel, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
KATP channel Clinical Trials 5 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on KATP channel. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 3 | 3 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
KATP channel Drug Approval Timeline (2009 - 2009)
The first and most recent drug approval for a KATP channel target was Nateglinide in 2009.
The lack of recent approvals suggests a saturated market or challenges in developing new KATP channel modulators.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 4 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on KATP channel. A trial counts if an approved drug acting on KATP channel is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.